Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jun-Yong Choi
With
Korea Institute of Oriental Medicine
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults aged ≥ 20 years
Patients who have understood and signed the informed consent.
Subjects who have been confirmed histologically and radiologically for non small cell lung cancer and are scheduled to receive treatment with immune checkpoint inhibitors
Subjects whose urine HCG are negative and who have agreed with the appropriate method of contraception in case of women of childbearing potential
Subjects who can fully communicate with their medical doctor about their symptoms or quality of life and who can fill out questionnaires
Subjects who can follow up during the clinical trial
Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
Hemoglobin ≥ 9g/dL
You may not be if
Subjects who are pregnant, breastfeeding, planning to become pregnant or women of childbearing potential who do not agree with the appropriate method of contraception
Subjects who have symptomatic and uncontrolled brain or central nervous system metastasis
Subjects who complain of uncontrolled pain despite using analgesics
Diastolic Blood Pressure\>100mmHg or Systolic Blood Pressure\>160mmHg
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels higher than 2.5 times the upper limit for normal
Creatinine level higher than 1.5 times the upper limit for normal
Subjects who have participated in other clinical trials within 1 months
Subjects with a history of serious drug allergies or who have hypersensitivity to the Investigational Product (the main ingredient and its components)
Subjects with autoimmune diseases
Subjects who have alcoholism or drug dependence
Subjects who have cognitive impairment or psychiatric problems
Subjects who have undergone surgery within 2 weeks
Subjects who took other herbal medicine or other medicines within 4 weeks
Subjects who have a medical condition that is likely to affect results or who are determined to be inappropriate to participate in this clinical trial at the investigator
